Mr. Maruthi Prasad Merdha a biochemist who has omni presence in pharmaceutical industry, started his career as an academician, QC analyst, biologist(Drug Discovery) and a marketeer, while working in a large pharma company in 2017 Mr Maruthi Prasad and Srikanth Singh a chemical engineer with 25+ years of experience has decided to start up an active nutraceutical company to integrate life with science, they then decided to deliver more into it to understand dynamics of nutraceuticals with pharmaceutical therapy, for which they formed a team of medical consultants, marketeers and chemical engineers.
As a team they started the literature search as well as nailed down few ingredients for their launch pipeline one of which is an imported ingredient from Italy also formulated with exclusive ingredients has helped the patients suffering from UV-Ray skinand launched the product named "UV -first" in the year 2018, which has helped at least 10,000+ sufferers of Melasma which is more aggravated due to sun rays. Now with this product in the South Indian market recurrence of Melasma has been a choice and for this an observational study was published in Dec 2020 by two of the Key Opinion Leaders from Dermatology fraternity from Hyderabad.
Earlier this year the team has ventured into neuro-psychiatry through their sister concern MPM healthcare also launched a product called "COGNIPHYX in the year 2020 December with an exclusive ingredient imported from Italy with the same has helped the patients with cognitive impairment, memory issues, depression and anxiety to live the better life and was synergistic to their ongoing pharmaceutical therapy.
With a mission to bridge this gap so every patient lives a longer healthier life they started the journey from Hyderabad we are on a pursuit of identifying and integrating the therapeutic nutraceuticals to optimise the patients wellness, we could establish the evidence of integrating new to nutraceuticals with pharmaceuticals in therapy areas of dermatology cosmetology & neuro-psychiatry
by offering products to augment and optimise the outcomes which are patient satisfactory adds Mr Maruthi Prasad. With its consistent as well as continuous efforts to optimise the pharmaceutical out-comes across the therapy areas the company is currently on the journey to build a strong pipeline of products to bring in newer augmenting therapies which are evidence-based and consumer centric.
BAMER BIO sources main ingredients for its products from Italy and Japan, formulates in India its first product UV-First was also sourced from Italy and formulated with active ingredients from India UV-First is a capsule which is now largely pre-scribed by dermatologists, the early findings of an observational study about this formulation revealed that it was particularly helpful for the patients with melasma/Hyperpigmentation a common skin condition that usually affects the facial skin and causes brown patches. Most patients would consume UV-First along with the prescribed drugs by Dermatologists, the study further demonstrated that it helped in quicker results and having a synergistic action-with drug therapy for recurrent Melasma treatment and currently there are 10,000+Patients, The team sourced an active ingredient for neuropsychiatry from Italy and formulated in India which is used by the key opinion leaders of Neuropsychiatry Fraternity in cognitive impairment, depression and anxiety.
This product has been in the market for approximately three months now which has 3000+ users currently BAM-ER Bio's products are being widely used in South
India & northern India the company wishes to expand and establish Pan India operations. The company has held meetings with key opinion leaders of medical
fraternity in the respective areas of dermatology, cosmetology & neuropsychiatry across the country which has conducted national advisory boards,
regional advisory boards and also a key opinion leader panel discussion in the therapy areas be taken upon to understand the augmentation of nutraceuticals
with pharmaceuticals in that particular therapy area, according to Mr Maruti. BAMER Bio-will soon be getting in investments and with that apart from growing
their products they wish to establish their own manufacturing unit, this year things are getting better and we hope to venture into untapped fields and help
as many as patients possible concludes Mr Maruthi.
click here for source of this content.
Bamerbio: Creating Products to integrate Life with Science
There is a rise in some chronic diseases like Cancer and NCDs (Non-communicable Diseases) due to the modern lifestyle. And this modern lifestyle has caused a lack of nutrition in individuals ranging from kids to old age people. The correct approach towards the right nutritional intake of food in day-to-day life is the key to keep oneself energetic and healthy. Mumbai-based Esperer Nutrition is filling this gap by providing broad-based nutritional support in chronic dis-ease management and NCDs. Esperer is a research-based Global Clinical Nutrition Organization that addresses preventive and chronic disease management nutritional interventions.
The company also offers the world's first research-based condition and cancer-specific nutrition supplements for hypermetabolic conditions. It also prioritizes drug-nutrient interactions and toxicity level of the drug as an important factor in chronic disease management. Esperer's DINI AXIS hypothesis highlights the interplay of diet, nutrition, and immunity, and targets at lowering the risk of NCDs. Esperer is holding 7 international patents in the space of clinical nutrition product formulation and allied researches.
Esperer's Cancer Disease Management and Supportive Nutrition
Esperer's research-based, condition, and site-specific nutrition portfolio address cancer condition specific nutritional intervention cancer disease management as complementary nutrition therapy. As Oncology deals with the prevention, diagnosis, and treatment of cancer, Esperer Onco Nutrition (EON) Therapy aids in nourishment, protection, and recovery to restore malnutrition during the prognosis. EON therapy mainly speaks on the nutritional interventions by offering nutritional preconditioning during chemo and post-chemo recovery stage-specific formulas as the world's first condition-specific cancer nutrition therapy.
Esperer'sproprietary research DINI AXIS (Diet-infection-nutrition-immunity) Axis addresses the sub-optimally treated infections via triggering various immunomodulatory path-ways and is set out to bring investigational validation of the phenomenon across various diseases. Esperer's integrated therapeutic
nutritional intervention will affect genetic mutation and expression boosting up immunity to com-bat the chronic inflammatory state caused by the pathogenic risk factors for patients having NCDs, thus improving their quality of life. EON foresees the launching of a range of products based on its DINI Axis in near future.
Esperer's academic platform E2RN (Esperer's Evidence-based Responsible Nutrition) concentrates on nutrition as a multidisciplinary and complementary therapy approach in case of both preventive and disease management areas. E2RN also takes the initiative of aggregating a commonly accepted definition for nutrition-specific interventions and nutrition-sensitive development.
Esperer's dedicated team of researchers, oncologists, nutritionists, scientists, and doctors address nutrition-al needs during the different stages of cancer treatment with a special focus on the recovery stage. Esperer Nutrition's motto is to give equitable access to optimal healthcare and support to all cancer patients despite their demographics. The company's initiative is to serve the neediest and vulnerable patient groups across pan-India by protecting them against a potential loss of life due to nutritional deficiencies in preventive and supportive nutrition.
Esperer Nutrition offers World's first research-based condition and stage-specific nutritional supplements for hypermetabolic conditions, exclusively for cancer patients
Esperer's products are innovation-driven and clinically evaluated for cancer disease management and NCDs. The company offers a clinically validated global standard nutraceutical range of formulations with 44 robust port-folio products spread over cancer nutrition, respiratory health, gut health, metabolic syndromes, hormonal health, etc. and more than four dozens of clinical nutrition products are in pipeline with EUGMPapproval. With a global marketing and distribution network, Esperer offers its high-quality products from USFDA and WHO GMP affirmed plants.
Driven by a huge diabetic population and increasing rural incomes, apathy towards dental health is changing fast and for better. Piscium Health Sciences is a Dental and Medical Devices business involved in research and development and providing improved solutions for dental practitioner. It was established in 2017 with headquarters in Navi Mumbai. Mr. Malay Dikshit and Dr Trupta Dikshit are the founders of the company.
The current portfolio of products offered by the company consists of Dental Burs and Alignates that have been developed by the Research and Development efforts of the company. Dental Burs are small rotary cutting tools that are used by the dentists for tooth preparation purposes, root canal treatment, treating caries, affixing dental crowns on patients etc.
Dental alginate impression material is another must-have in the dentist’s office. They developed this product from scratch using help from Institute of Chemical Technology, Mumbai. The company has a full suite of over a hundred variants in Nano Diamond Dental Burs which are useful across multiple dental procedures. It is also collaborating with dentists to develop custom- made designs and kits.
The Country Is Mostly Dependent On Imports For Dental Consumables
According to National oral health survey, 80 percent of Indians suffer from a dental
ailment and less than 45 percent have ever visited a dentist. India is dependent on imports to fulfil dental consumables demand. Piscium realised that the dental bur, a basic necessity at the dental clinic is all imported and decided to manufacture them in India. Using a technique called chemical vapor deposition or CVD, they grow nano diamonds on the sharp blades of dental burs to get superior performance. They have a patent in this Subject.
Piscium has a small yet full fledged manufacturing capacity in Navi Mumbai which manufactures burs and dental alginates. The machine for nano diamond coating is designed and fabricated in India. Capacity expansion plans for both Alginates and Burs are firmed up.
Diamond made by using CVD technology has the hardness led cutting ability and near zero coefficient of friction. Synthetic diamond or diamond like carbon (DLC) deposition is used extensively in the automobile industry for plungers and small parts where the frictionless motion is critical. CVD Diamond is coated on industrial tools in a handful of locations in the world and being used for graphite machining, aerospace machining and electronics where accuracy is of utmost importance. DLC coating on heart stents has the potential to make the stent resistant to recalcification.
The current portfolio of products offered by the company consists of Dental Burs and Alignates that have been developed by the Research and Development efforts of the company
The commercial launch of CVD Diamond coated medical cutting devices probably hasn’t happened anywhere else.
After Market Testing Stage, Piscium will Upscale Production
The company is at a market testing stage in Mumbai and a small team of sales executives remain in constant touch with the dentists. The dentists are enthusiastic about indigenous products and the new innovation looks promising to them. Out of the 500 dentists the company reached out to, over 200 of them have bought the products.After scaling up the capacity, Piscium will be poised for national launch.
Upscaling production is the nearest priority for the company now along with geographical expansion. The creative agency at the company, Medulla, uses digital medium to deliver similar outcomes as the conventional promotional routes like expos or CMEs. The company plans to launch two new innovations in a year. After upscaling, the company is looking forward to a series A by the year end.